Home » Venture Capital » Current Portfolio

Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Company Description Statussort icon Initial Date
<a href="/venture-capital/all-companies/taris-biomedical-inc">TARIS Biomedical, Inc.</a> Developing local minimally-invasive drug-device convergence products. Private 2008 View Profile
<a href="/venture-capital/all-companies/eleven-biotherapeutics-inc">Eleven Biotherapeutics, Inc.</a> Creating novel and differentiated biotherapeutics: first-of-a-kind protein-based drugs. Private 2008 View Profile
<a href="/venture-capital/all-companies/novomer-inc">Novomer, Inc.</a> Pioneering a family of high performance, environmentally responsible polymers and chemical intermediates. Private 2007 View Profile
<a href="/venture-capital/all-companies/oasys-water-inc">Oasys Water, Inc.</a> Develops systems to maximize fresh water availability while reducing the energy and cost associated with desalination. Private 2009 View Profile
<a href="/venture-capital/all-companies/visterra-inc">Visterra, Inc.</a> Discovering and developing innovative products that will transform the prevention and treatment of infectious diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/mascoma-corporation">Mascoma Corporation</a> Developing environmentally sustainable, low cost, low carbon biofuels from cellulosic biomass. Private 2006 View Profile
<a href="/venture-capital/all-companies/moderna">moderna</a> Pioneering an entirely new drug modality using messenger RNA therapeutics™. Private 2010 View Profile
<a href="/venture-capital/all-companies/ensemble-therapeutics-corporation">Ensemble Therapeutics Corporation</a> Deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as “Ensemblins”. Private 2004 View Profile
<a href="/venture-capital/all-companies/quanterix-corporation">Quanterix Corporation</a> Developing a novel platform for single molecule analysis of proteins. Private 2007 View Profile
<a href="/venture-capital/all-companies/seahorse-bioscience-inc">Seahorse Bioscience, Inc.</a> Analytical instruments and consumable labware products for biological research and drug discovery. Private 2001 View Profile
<a href="/venture-capital/all-companies/selventa">Selventa</a> Analyzes molecular patient data, accelerates the development process and clarifies decisions on therapeutics and diagnostics Private 2001 View Profile
<a href="/venture-capital/all-companies/medidametrics-inc">MedidaMETRICS, Inc.</a> Developing activity-based costing systems for healthcare providers. Private 2010 View Profile
<a href="/venture-capital/all-companies/pronutria">Pronutria</a> Transforming global nutrition. Private 2010 View Profile
<a href="/venture-capital/all-companies/seres-health">Seres Health</a> Seres Health is pioneering a new class of therapeutics that, for the first time, catalyzes health in multiple important therapeutic areas. Private 2012 View Profile
<a href="/venture-capital/all-companies/midori-renewables-inc">Midori Renewables Inc.</a> Commercializing chemical catalysts for upgrading waste biomass to fuels, chemicals, and materials. Private 2010 View Profile
<a href="/venture-capital/all-companies/aerodesigns-inc">AeroDesigns Inc.</a> Pioneering air-based delivery systems to reimagine the consumption of food, nutrients and medications. Private 2011 View Profile
<a href="/venture-capital/all-companies/blend-therapeutics-inc">Blend Therapeutics Inc.</a> Discovering new classes of medicines that have unique modes of action to result in drugs with differentiated therapeutic properties. Private 2012 View Profile
<a href="/venture-capital/all-companies/tangent-medical-technologies-inc">Tangent Medical Technologies Inc.</a> Tangent Medical Technologies is advancing infusion therapy by improving catheter stability, patient comfort and healthcare worker safety with its proprietary, intravenous catheters and associated products. Private 2011 View Profile
<a href="/venture-capital/all-companies/syros-pharmaceuticals-0">Syros Pharmaceuticals</a> Life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Private 2012 View Profile